MX2023010322A - Método para tratar una afección usando una dosis terapéuticamente efectiva del inhibidor de malt1 jnj-67856633 (1-(1-(1- oxo-1,2-dihidroisoquinolina-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piriidin-4-il)-1h-pirazol-4-carboxamida). - Google Patents
Método para tratar una afección usando una dosis terapéuticamente efectiva del inhibidor de malt1 jnj-67856633 (1-(1-(1- oxo-1,2-dihidroisoquinolina-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piriidin-4-il)-1h-pirazol-4-carboxamida).Info
- Publication number
- MX2023010322A MX2023010322A MX2023010322A MX2023010322A MX2023010322A MX 2023010322 A MX2023010322 A MX 2023010322A MX 2023010322 A MX2023010322 A MX 2023010322A MX 2023010322 A MX2023010322 A MX 2023010322A MX 2023010322 A MX2023010322 A MX 2023010322A
- Authority
- MX
- Mexico
- Prior art keywords
- trifluoromethyl
- therapeutically effective
- effective dose
- dihydroisoquinolin
- pyridin
- Prior art date
Links
- TWJGQZBSEMDPQP-UHFFFAOYSA-N 2-chloro-n-[4-[5-(3,4-dichlorophenyl)-3-(2-methoxyethoxy)-1,2,4-triazol-1-yl]phenyl]acetamide Chemical compound C=1C=C(NC(=O)CCl)C=CC=1N1N=C(OCCOC)N=C1C1=CC=C(Cl)C(Cl)=C1 TWJGQZBSEMDPQP-UHFFFAOYSA-N 0.000 title 1
- 229940122339 MALT1 inhibitor Drugs 0.000 title 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 101150113681 MALT1 gene Proteins 0.000 abstract 1
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 abstract 1
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2021/051776 WO2022185097A1 (en) | 2021-03-03 | 2021-03-03 | Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010322A true MX2023010322A (es) | 2023-11-24 |
Family
ID=74860360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010322A MX2023010322A (es) | 2021-03-03 | 2021-03-03 | Método para tratar una afección usando una dosis terapéuticamente efectiva del inhibidor de malt1 jnj-67856633 (1-(1-(1- oxo-1,2-dihidroisoquinolina-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piriidin-4-il)-1h-pirazol-4-carboxamida). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299376A1 (https=) |
| EP (1) | EP4301364A1 (https=) |
| JP (1) | JP2024508890A (https=) |
| KR (1) | KR20230154227A (https=) |
| CN (1) | CN117279639A (https=) |
| AU (1) | AU2021431485A1 (https=) |
| BR (1) | BR112023017689A2 (https=) |
| CA (1) | CA3212339A1 (https=) |
| MX (1) | MX2023010322A (https=) |
| WO (1) | WO2022185097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| CN118451068A (zh) * | 2021-12-30 | 2024-08-06 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US12269813B2 (en) | 2019-02-22 | 2025-04-08 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate |
| US20220175760A1 (en) * | 2019-02-22 | 2022-06-09 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
-
2021
- 2021-03-03 BR BR112023017689A patent/BR112023017689A2/pt unknown
- 2021-03-03 JP JP2023553246A patent/JP2024508890A/ja not_active Withdrawn
- 2021-03-03 US US18/279,556 patent/US20240299376A1/en active Pending
- 2021-03-03 CN CN202180097818.8A patent/CN117279639A/zh active Pending
- 2021-03-03 AU AU2021431485A patent/AU2021431485A1/en not_active Abandoned
- 2021-03-03 MX MX2023010322A patent/MX2023010322A/es unknown
- 2021-03-03 KR KR1020237033580A patent/KR20230154227A/ko active Pending
- 2021-03-03 CA CA3212339A patent/CA3212339A1/en active Pending
- 2021-03-03 WO PCT/IB2021/051776 patent/WO2022185097A1/en not_active Ceased
- 2021-03-03 EP EP21710602.0A patent/EP4301364A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4301364A1 (en) | 2024-01-10 |
| WO2022185097A1 (en) | 2022-09-09 |
| CN117279639A (zh) | 2023-12-22 |
| JP2024508890A (ja) | 2024-02-28 |
| AU2021431485A1 (en) | 2023-10-19 |
| BR112023017689A2 (pt) | 2023-11-14 |
| US20240299376A1 (en) | 2024-09-12 |
| KR20230154227A (ko) | 2023-11-07 |
| CA3212339A1 (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010322A (es) | Método para tratar una afección usando una dosis terapéuticamente efectiva del inhibidor de malt1 jnj-67856633 (1-(1-(1- oxo-1,2-dihidroisoquinolina-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piriidin-4-il)-1h-pirazol-4-carboxamida). | |
| US9205086B2 (en) | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2023010314A (es) | Terapia de combinación usando un inhibidor de malt1 y un inhibidor de btk. | |
| JOP20250246A1 (ar) | مثبطات kras | |
| US20130171105A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor | |
| DK2531191T3 (en) | Sigma ligands for use in the prevention and / or treatment of post-operative pain | |
| CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| JPWO2020085493A5 (https=) | ||
| JP2009538897A5 (https=) | ||
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP2016525122A5 (https=) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| JP2019535658A5 (https=) | ||
| MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| FI3661510T3 (fi) | Menetelmiä käyttäytymismuutosten hoitamiseksi | |
| MA60154B1 (fr) | Inhibiteurs de line-1 pour traiter une maladie | |
| CO2022005861A2 (es) | Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| JP2019065009A5 (https=) |